0
     

Report Added
Report already added
Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fallopian Tube Cancer - Drugs In Development, 2022, provides an overview of the Fallopian Tube Cancer (Oncology) pipeline landscape.

Fallopian tube cancer is also called tubal cancer. It develops in the fallopian tubes, which serve as a connection between the ovaries and the uterus. It occurs very rarely. The common symptoms of fallopian tube cancer may include abnormal vaginal bleeding, especially after menopause, abdominal pain or a feeling of pressure in the abdomen, abnormal vaginal discharge that is white, clear or pinkish and a pelvic mass at the time of diagnosis, which is present in up to two-thirds of patients. Usually, cancer metastasizes from other parts of the body such as the ovaries or endometrium to the fallopian tubes. Fallopian tube cancer treatment depends on age, the desire to have children, type and stage of the tumor. It usually involves surgery followed by chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fallopian Tube Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Fallopian Tube Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fallopian Tube Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Fallopian Tube Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 27, 102, 78, 2 and 10 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 8 and 1 molecules, respectively.

Fallopian Tube Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fallopian Tube Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Fallopian Tube Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fallopian Tube Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fallopian Tube Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fallopian Tube Cancer (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fallopian Tube Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fallopian Tube Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Fallopian Tube Cancer - Overview
Fallopian Tube Cancer - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fallopian Tube Cancer - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fallopian Tube Cancer - Companies Involved in Therapeutics Development
Fallopian Tube Cancer - Drug Profiles
Fallopian Tube Cancer - Dormant Projects
Fallopian Tube Cancer - Discontinued Products
Fallopian Tube Cancer - Product Development Milestones
Featured News & Press Releases
Jul 22, 2022: EMA recommends restricting use of cancer medicine Rubraca
Jul 05, 2022: EMA recommends granting a marketing authorisation for biosimilar Bevacizumab
May 31, 2022: Greenfire Bio to update progress on phase 1 clinical trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022
May 19, 2022: EMA starts review of rucaparib
Feb 24, 2022: Once-a-day capsule for people with some forms of ovarian, fallopian tube and peritoneal cancer recommended for routine use in the NHS
Dec 10, 2021: Inceptua receives formal approval of the transfer of Oasmia’s marketing authorization for Apealea
Dec 02, 2021: BeiGene announces inclusion in the China National Reimbursement Drug List (NRDL) first listing for Pamiparib
Feb 25, 2021: Viatris receives positive CHMP opinion for Abevmy for use as treatment of various cancers
Dec 28, 2020: Zai Lab announces inclusion of ZEJULA (Niraparib) in China’s National Reimbursement Drug List
Oct 05, 2020: Elevar Therapeutics and Taiba Middle East FZ partner to commercialize Apealea (paclitaxel micellar) in the Middle East and North Africa region
Jul 27, 2020: Elevar Therapeutics and Tanner Pharma Group announce global named patient program to provide access to Apealea (paclitaxel micellar)
Jun 22, 2020: Preclinical data for PRGN-3005 UltraCAR-T demonstrate superior expansion and persistence of UltraCAR-T compared to traditional CAR-T
Apr 30, 2020: GSK gets FDA approval for expanded use of ovarian cancer drug Zejula
Apr 20, 2020: Sutro Biopharma to host conference call, to provide clinical update on its STRO-002 Antibody-Drug Conjugate
Mar 16, 2020: Zai Lab announces acceptance of sNDA submission of ZEJULA (Niraparib) for first-line maintenance treatment of ovarian cancer in China by the NMPA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Fallopian Tube Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Fallopian Tube Cancer - Dormant Projects, 2022
Fallopian Tube Cancer - Discontinued Products, 2022
Fallopian Tube Cancer - Discontinued Products, 2022 (Contd..1)

List of Figures
Number of Products under Development for Fallopian Tube Cancer, 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Top 10 Molecule Types, 2022
Number of Products by Stage and Top 10 Molecule Types, 2022

Report Title: Fallopian Tube Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update


Your Details
Valid Invalid number

SELECT A FORMAT

ADD TO CART BUY NOW